<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39364147</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs.</ArticleTitle><Pagination><StartPage>1468775</StartPage><MedlinePgn>1468775</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1468775</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2024.1468775</ELocationID><Abstract><AbstractText>Minks, cats, and some other species of carnivores are susceptible of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and have a high risk of transmitting SARS-CoV-2 to humans. The development of animal vaccines can be an effective measure to protect animals against SARS-CoV-2 and reduce the potential risk of human infection. We previously developed a messenger ribonucleic acid (mRNA) vaccine SYS6006 that has been proven to be an efficient coronavirus disease 2019 (COVID-19) vaccine widely used in humans. Here, we further evaluated the safety and immunogenicity of SYS6006 as an animal COVID-19 vaccine candidate for SARS-CoV-2 susceptible animals or wild animals. SYS6006 was safe and immunogenic in mice and completely protected mice against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. SYS6006 was able to induce neutralizing antibodies against the SARS-CoV-2 wild-type, Delta, and Omicron BA.2 strain on day 7 after prime immunization, and two doses of immunization could enhance the neutralizing antibody responses and produce long-lasting potent antibodies for more than 8 months in minks and cats, blue foxes, and raccoon dogs, while all immunized animals had no abnormal clinical signs during immunization. These results provided here warrant further development of this safe and efficacious mRNA vaccine platform against animal COVID-19.</AbstractText><CopyrightInformation>Copyright © 2024 Huo, Wang, Li, Xiao, Wang, Ge, Zhong, Wen, Wang, Lang, Chen, Wang, Wang, Wang, He, Guan, Shuai and Bu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Huo</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Jinming</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Chan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC Pharmaceutical Group Co., Ltd., Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Jinying</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Gongxun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Zhiyuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Qiaoling</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC Pharmaceutical Group Co., Ltd., Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC Pharmaceutical Group Co., Ltd., Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zilong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC Pharmaceutical Group Co., Ltd., Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinliang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xijun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xijun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Yuntao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuai</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Zhigao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000722716">SYS6006 COVID-19 vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002415" MajorTopicYN="N">Cats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046031" MajorTopicYN="Y">Raccoon Dogs</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005589" MajorTopicYN="Y">Foxes</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="Y">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">susceptible animals</Keyword></KeywordList><CoiStatement>Authors CL, QL, LC, and ZLW were employed by CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>11</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364147</ArticleId><ArticleId IdType="pmc">PMC11446887</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2024.1468775</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cao Y. L., Wang J., Jian F. C., Xiao T. H., Song W. L., Yisimayi A., et al. . (2022). Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663. doi: 10.1038/s41586-021-04385-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04385-3</ArticleId><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli A. M., Peacock T. P., Thorne L. G., Harvey W. T., Hughes J., Peacock S. J., et al. . (2023). SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162–177. doi: 10.1038/s41579-022-00841-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00841-7</ArticleId><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Caserta L. C., Martins M., Butt S. L., Hollingshead N. A., Covaleda L. M., Ahmed S., et al. . (2023). White-tailed deer may serve as a wildlife reservoir for nearly extinct SARS-CoV-2 variants of concern. Proc. Natl. Acad. Sci. USA. 120 (6), e2215067120. doi: 10.1073/pnas.2215067120</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2215067120</ArticleId><ArticleId IdType="pmc">PMC9963525</ArticleId><ArticleId IdType="pubmed">36719912</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S., Harper C., Vrbicky K., Walsh S. R., Essink B., Brosz A., et al. . (2022). A bivalent omicron-containing booster vaccine against Covid-19. N Engl. J. Med. 387, 1279–1291. doi: 10.1056/NEJMoa2208343</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2208343</ArticleId><ArticleId IdType="pmc">PMC9511634</ArticleId><ArticleId IdType="pubmed">36112399</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavda V. P., Feehan J., Apostolopoulos V. (2021). A veterinary vaccine for SARS-CoV-2: The first COVID-19 vaccine for animals. Vaccines (Basel) 9 (6), 631. doi: 10.3390/vaccines9060631</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9060631</ArticleId><ArticleId IdType="pmc">PMC8228738</ArticleId><ArticleId IdType="pubmed">34200587</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G. L., Qiu Y. Z., Wu K. Q., Wu Y., Wang Y. H., Zou Y. Y., et al. . (2023). Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials. Hum. Vaccines Immunotherapeutics 19 (3), 2285089. doi: 10.1080/21645515.2023.2285089</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2285089</ArticleId><ArticleId IdType="pmc">PMC10760391</ArticleId><ArticleId IdType="pubmed">38111106</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi A., Koch M., Wu K., Chu L., Ma L. Z., Hill A., et al. . (2021). Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat. Med. 27, 2025–2031. doi: 10.1038/s41591-021-01527-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01527-y</ArticleId><ArticleId IdType="pmc">PMC8604720</ArticleId><ArticleId IdType="pubmed">34526698</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary O. P., Priyanka, Saied A. A. (2022). COVID-19 vaccination in animals: A strategy for combating the global outbreak. Int. J. Surg. 105, 106848. doi: 10.1016/j.ijsu.2022.106848</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2022.106848</ArticleId><ArticleId IdType="pmc">PMC9398550</ArticleId><ArticleId IdType="pubmed">36028140</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckstrand C. D., Baldwin T. J., Rood K. A., Clayton M. J., Lott J. K., Wolking R. M., et al. . (2021). An outbreak of SARS-CoV-2 with high mortality in mink (Neovison vison) on multiple Utah farms. PLoS Pathog. 17 (11), e1009952. doi: 10.1371/journal.ppat.1009952</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009952</ArticleId><ArticleId IdType="pmc">PMC8589170</ArticleId><ArticleId IdType="pubmed">34767598</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Phillips D. J., White T., Sayal H., Aley P. K., Bibi S., et al. . (2021). Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032–2040. doi: 10.1038/s41591-021-01540-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P. B., Montefiori D. C., McDermott A., Fong Y. Y., Benkeser D., Deng W. P., et al. . (2022). Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50. doi: 10.1126/science.abm3425</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregorio G. E. V., Catacutan A. M. B., Perez M. L. M., Dans L. F. (2024). Efficacy, effectiveness, and safety of COVID-19 vaccine compared to placebo in preventing COVID-19 infection among 12-17 years old: A systematic review. Acta Med. Philipp 58, 41–53. doi: 10.47895/amp.v58i7.7930</Citation><ArticleIdList><ArticleId IdType="doi">10.47895/amp.v58i7.7930</ArticleId><ArticleId IdType="pmc">PMC11168957</ArticleId><ArticleId IdType="pubmed">38882914</ArticleId></ArticleIdList></Reference><Reference><Citation>He X. M., He C., Hong W. Q., Yang J. Y., Wei X. W. (2023). Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. Medicinal Res. Rev. 43, 932–971. doi: 10.1002/med.21941</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21941</ArticleId><ArticleId IdType="pubmed">36929527</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Qiu Y., Luo L., Wu J., Hu D., Zhong X., et al. . (2024). Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine. J. Med. Virol. 96, e29542. doi: 10.1002/jmv.29542</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29542</ArticleId><ArticleId IdType="pubmed">38506170</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam A., Ferdous J., Islam S., Abu Sayeed M., Rahman M. K., Saha O., et al. . (2022). Transmission dynamics and susceptibility patterns of SARS-CoV-2 in domestic, farmed and wild animals: Sustainable One Health surveillance for conservation and public health to prevent future epidemics and pandemics. Transboundary Emerging Dis. 69, 2523–2543. doi: 10.1111/tbed.14356</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tbed.14356</ArticleId><ArticleId IdType="pmc">PMC8662162</ArticleId><ArticleId IdType="pubmed">34694705</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin F., Qiu Y., Wu Z., Wang Y. H., Cai C., Fu L., et al. . (2024). Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial. Vaccine. 42 (7), 1561–1570 doi: 10.1016/j.vaccine.2024.01.098</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.01.098</ArticleId><ArticleId IdType="pubmed">38365485</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam M., Daoud G. (2022). mRNA vaccines: Past, present, future. Asian J. Pharm. Sci. 17, 491–522. doi: 10.1016/j.ajps.2022.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajps.2022.05.003</ArticleId><ArticleId IdType="pmc">PMC9459002</ArticleId><ArticleId IdType="pubmed">36105317</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopmans M. (2021). SARS-CoV-2 and the human-animal interface: outbreaks on mink farms. Lancet Infect. Dis. 21, 18–19. doi: 10.1016/1473-3099(20)30912-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/1473-3099(20)30912-9</ArticleId><ArticleId IdType="pmc">PMC7832374</ArticleId><ArticleId IdType="pubmed">33227234</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D. Y., Zeng D. L., Gilbert P. B. (2021). Evaluating the long-term efficacy of coronavirus disease 2019 (COVID-19) vaccines. Clin. Infect. Dis. 73, 1927–1939. doi: 10.1093/cid/ciab226</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab226</ArticleId><ArticleId IdType="pmc">PMC7989522</ArticleId><ArticleId IdType="pubmed">33693529</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L., Sikkema R. S., Velkers F. C., Nieuwenhuijse D. F., Fischer E. A. J., Meijer P. A., et al. . (2021). Adaptation, spread and transmission of SARS-CoV-2 in farmed minks and associated humans in the Netherlands. Nat. Commun. 12 (1), 6802. doi: 10.1038/s41467-021-27096-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27096-9</ArticleId><ArticleId IdType="pmc">PMC8611045</ArticleId><ArticleId IdType="pubmed">34815406</ArticleId></ArticleIdList></Reference><Reference><Citation>Munnink B. B. O., Sikkema R. S., Nieuwenhuijse D. F., Molenaar R. J., Munger E., Molenkamp R., et al. . (2021). Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science 371, 172–177. doi: 10.1126/science.abe5901</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe5901</ArticleId><ArticleId IdType="pmc">PMC7857398</ArticleId><ArticleId IdType="pubmed">33172935</ArticleId></ArticleIdList></Reference><Reference><Citation>Nerpel A., Käsbohrer A., Walzer C., Desvars-Larrive A. (2023). Data on SARS-CoV-2 events in animals: Mind the gap! One Health 17, 100653. doi: 10.1016/j.onehlt.2023.100653</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.onehlt.2023.100653</ArticleId><ArticleId IdType="pmc">PMC10665207</ArticleId><ArticleId IdType="pubmed">38024278</ArticleId></ArticleIdList></Reference><Reference><Citation>Nooruzzaman M., Diel D. G. (2023). Infection dynamics, pathogenesis, and immunity to SARS-CoV-2 in naturally susceptible animal species. J. Immunol. 211, 1195–1201. doi: 10.4049/jimmunol.2300378</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2300378</ArticleId><ArticleId IdType="pmc">PMC10558081</ArticleId><ArticleId IdType="pubmed">37782853</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N., Hogan M. J., Porter F. W., Weissman D. (2018). mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discovery 17, 261–279. doi: 10.1038/nrd.2017.243</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R., Kaki M., Potluri V. S., Kahar P., Khanna D. (2022). A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna &amp; Johnson &amp; Johnson. Hum. Vaccin Immunother. 18, 2002083. doi: 10.1080/21645515.2021.2002083</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.2002083</ArticleId><ArticleId IdType="pmc">PMC8862159</ArticleId><ArticleId IdType="pubmed">35130825</ArticleId></ArticleIdList></Reference><Reference><Citation>Puranik A., Lenehan P. J., Silvert E., Niesen M. J. M., CorChado-Garcia J., O'Horo J. C., et al. . (2022). Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. Med 3, 28–41. doi: 10.1016/j.medj.2021.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.12.002</ArticleId><ArticleId IdType="pmc">PMC8664708</ArticleId><ArticleId IdType="pubmed">34927113</ArticleId></ArticleIdList></Reference><Reference><Citation>Sailleau C., Dumarest M., Vanhomwegen J., Delaplace M., Caro V., Kwasiborski A., et al. . (2020). First detection and genome sequencing of SARS-CoV-2 in an infected cat in France. Transboundary Emerging Dis. 67, 2324–2328. doi: 10.1111/tbed.13659</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tbed.13659</ArticleId><ArticleId IdType="pmc">PMC7300955</ArticleId><ArticleId IdType="pubmed">32500944</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J. Z., Wen Z. Y., Zhong G. X., Yang H. L., Wang C., Huang B. Y., et al. . (2020. a). Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 368, 1016–1020. doi: 10.1126/science.abb7015</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb7015</ArticleId><ArticleId IdType="pmc">PMC7164390</ArticleId><ArticleId IdType="pubmed">32269068</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Wang G., Cai X. P., Deng J. W., Zheng L., Zhu H. H., et al. . (2020. b). An overview of COVID-19. J. Zhejiang Univ Sci. B 21, 343–360. doi: 10.1631/jzus.B2000083</Citation><ArticleIdList><ArticleId IdType="doi">10.1631/jzus.B2000083</ArticleId><ArticleId IdType="pmc">PMC7205601</ArticleId><ArticleId IdType="pubmed">32425000</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai L., Zhong G. X., Yuan Q., Wen Z. Y., Wang C., He X. J., et al. . (2021). Replication, pathogenicity, and transmission of SARS-CoV-2 in minks. Natl. Sci. Rev. 8(3), nwaa291. doi: 10.1093/nsr/nwaa291</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa291</ArticleId><ArticleId IdType="pmc">PMC7798852</ArticleId><ArticleId IdType="pubmed">34676095</ArticleId></ArticleIdList></Reference><Reference><Citation>Sila T., Sunghan J., Laochareonsuk W., Surasombatpattana S., Kongkamol C., Ingviya T., et al. . (2022). Suspected cat-to-human transmission of SARS-CoV-2, Thailand, July-September 2021. Emerging Infect. Dis. 28, 1485–1488. doi: 10.3201/eid2807.212605</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2807.212605</ArticleId><ArticleId IdType="pmc">PMC9239874</ArticleId><ArticleId IdType="pubmed">35666777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sit T. H. C., Brackman C. J., Ip S. M., Tam K. W. S., Law P. Y. T., To E. M. W., et al. . (2020). Infection of dogs with SARS-Cov-2. Nature 586, 776–778. doi: 10.1038/s41586-020-2334-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2334-5</ArticleId><ArticleId IdType="pmc">PMC7606701</ArticleId><ArticleId IdType="pubmed">32408337</ArticleId></ArticleIdList></Reference><Reference><Citation>Slifka M. K., Amanna I. (2014). How advances in immunology provide insight into improving vaccine efficacy. Vaccine 32, 2948–2957. doi: 10.1016/j.vaccine.2014.03.078</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.03.078</ArticleId><ArticleId IdType="pmc">PMC4096845</ArticleId><ArticleId IdType="pubmed">24709587</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y. W., Qiu Y. Z., Wang Y. H., Xu Y., Huang C. C., Zhang Q., et al. . (2024). Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial. Vaccine. 42 (9), 2438–2447. doi: 10.1016/j.vaccine.2024.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.03.005</ArticleId><ArticleId IdType="pubmed">38461050</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. L., Shuai L., Wang C., Liu R. Q., He X. J., Zhang X. F., et al. . (2020). Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein Cell 11, 776–782. doi: 10.1007/s13238-020-00767-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-020-00767-x</ArticleId><ArticleId IdType="pmc">PMC7401472</ArticleId><ArticleId IdType="pubmed">32749592</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. J., Ge J. Y., Hu S., Wang Q. H., Wen Z. Y., Chen H. L., et al. . (2006). Efficacy of DNA immunization with F and G protein genes of Nipah virus. Impact Emerging Zoonotic Dis. Anim. Health 1081, 243–245. doi: 10.1196/annals.1373.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1373.029</ArticleId><ArticleId IdType="pubmed">17135518</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO  (2023). The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline. Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed March 30, 2023).</Citation></Reference><Reference><Citation>
WHO  (2024). Coronavirus disease (COVID-19) Situation Dashboard. Available online at: https://covid19.who.int/WHO-COVID-19-global-data. (Accessed June 30, 2024).</Citation></Reference><Reference><Citation>Xu K., Lei W. W., Kang B., Yang H. Y., Wang Y. J., Lu Y. L., et al. . (2023). A novel mRNA vaccine, SYS6006, against SARS-CoV-2. Front. Immunol. 13. doi: 10.3389/fimmu.2022.1051576</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1051576</ArticleId><ArticleId IdType="pmc">PMC9849951</ArticleId><ArticleId IdType="pubmed">36685587</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Zhang H. J., Gao J. D., Huang K., Yang Y., Hui X. F., et al. . (2020). A serological survey of SARS-CoV-2 in cat in Wuhan. Emerging Microbes Infections 9, 2013–2019. doi: 10.1080/22221751.2020.1817796</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1817796</ArticleId><ArticleId IdType="pmc">PMC7534315</ArticleId><ArticleId IdType="pubmed">32867625</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P., Yang X. L., Wang X. G., Hu B., Zhang L., Zhang W., et al. . (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273. doi: 10.1038/s41586-020-2012-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y. B., Zhi H. L., Teng Y. (2023). The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. J. Med. Virol. 95, e28138. doi: 10.1002/jmv.28138</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28138</ArticleId><ArticleId IdType="pmc">PMC9538491</ArticleId><ArticleId IdType="pubmed">36097349</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>